Abstract PS5-01-24: Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trial
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: P. R. POHLMANN, N. Chen, J. A. Mouabbi, N. Jahan, M. Rampurwala, A. Discacciati, M. Eklund, A. Chapple, G. L. Hirst, S. Venters, L. Brown-Swigart, E. Petricoin, A. D. Borowsky, L. J. van 't Veer, A. L. Delson, S. M. Asare, S. Jaffari, P. Henderson, D. Tripathy, L. J. Esserman, H. S. Rugo, R. Nanda, E. Stringer-Reasor, D. Yee, F. Meric-Bernstam, D. A. Potter
Institutions: The University of Texas MD Anderson Cancer Center, University of Chicago, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, University of Chicago Medical Center, Karolinska Institutet, Quantum Leap Healthcare Collaborative, University of California, San Francisco, George Mason University, University of California Davis Medical Center, University of California, Davis, UCSF Helen Diller Family Comprehensive Cancer Center, City Of Hope National Medical Center, City of Hope, University of Minnesota, Masonic Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129438940
Cites:
Cited by:
Related to: